Thus, it would be of interest to study how other FLT3 inhibitors (midostaurin and gilteritinib) used in clinics in combination with standard chemotherapies regulate autophagy in AML patients harboring FLT3-ITD mutations. The gene discussed is FLT3; the disease is acute myeloid leukemia.